Condition: Behçet Disease · Sponsor: Amgen
The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \< 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Hospices Civils de Lyon Hopital Femme Mere Enfant | Bron, France | Recruiting |
| Hopital Necker Enfants Malades | Paris, France | Terminated |
| Hopital Robert Debre | Paris, France | Recruiting |
| Agia Sofia Children Hospital | Athens, Greece | Recruiting |
| Attikon University General Hospital | Athens, Greece | Recruiting |
| General Hospital of Thessaloniki Ippokrateio | Thessaloniki, Greece | Recruiting |
| Meir Medical Center | Kfar Saba, Israel | Recruiting |
| Ospedale Santissima Annunziata | Chieti, Italy | Terminated |
| IRCCS Istituto Giannina Gaslini | Genova, Italy | Recruiting |
| Azienda Socio Sanitaria Territoriale Centro Specialistico Ortopedico Traumatologico Gaetano Pini | Milan, Italy | Terminated |
| IRCCS Ospedale Pediatrico Bambino Gesu | Roma, Italy | Recruiting |
| Hospital Universitario Virgen del Rocio | Seville, Andalusia, Spain | Recruiting |
+ 15 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04528082